Sarah Hellems
Life Sciences Consulting Actuary
Tampa, FL, US
Publications
Read their latest work
Article
The expanding presence of the 340B Drug Pricing Program and implications of CMS's CY 2027 OPPS rule
17 November 2026 - by Katherine M. Holcomb, Maggie Alston, Massey Whorley, Sarah Hellems, Philip Nelson
A change to OPPS payments for 340B drugs could have material financial effects on non-340B hospitals, Medicare Advantage plans, and beneficiaries.